A Open-Label Extension Study Of CP-690,550 As Maintenance Therapy In Patients With Crohn's Disease
Phase of Trial: Phase II
Latest Information Update: 05 Mar 2018
At a glance
- Drugs Tofacitinib (Primary)
- Indications Crohn's disease
- Focus Adverse reactions
- Sponsors Pfizer
- 10 Jun 2017 Biomarkers information updated
- 16 Aug 2016 Status changed from recruiting to completed.
- 16 Aug 2016 This trial was completed in Bulgaria (End date: 25 Jul 2016).